Episode 209: Blast Crisis
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Episode 209: Blast Crisis
-
Narrated by:
-
By:
About this listen
We dive into the recognition and management of blast crisis.
Hosts:
Sadakat Chowdhury, MD
Brian Gilberti, MD
- Blast crisis is an oncologic emergency, most commonly seen in chronic myeloid leukemia (CML).
- Defined by:
- >20% blasts in peripheral blood or bone marrow.
- May include extramedullary blast proliferation.
- Without treatment, median survival is only 3–6 months.
- Usually occurs in CML, but also in:
- Myeloproliferative neoplasms (MPNs)
- Myelodysplastic syndromes (MDS)
- Transition from chronic to blast phase often reflects disease progression or treatment resistance.
- 10% of CML patients progress to blast crisis.
- Risk increased in:
- Patients refractory to tyrosine kinase inhibitors (e.g., imatinib).
- Those with Philadelphia chromosome abnormalities.
- WBC >100,000, which increases risk for leukostasis.
- Symptoms often stem from pancytopenia and leukostasis:
- Anemia: fatigue, malaise.
- Functional neutropenia: high WBC count, but increased infection/sepsis risk.
- Thrombocytopenia: bleeding, bruising.
- Leukostasis/hyperviscosity effects by system:
- Neurologic: confusion, visual changes, stroke-like symptoms.
- Cardiopulmonary: ARDS, myocardial injury.
- Others: priapism, limb ischemia, bowel infarction.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.